Home/Filings/4/0001104659-19-051596
4//SEC Filing

PRICE MICHAEL DENNIS 4

Accession 0001104659-19-051596

CIK 0000827809other

Filed

Sep 25, 8:00 PM ET

Accepted

Sep 26, 6:30 PM ET

Size

5.5 KB

Accession

0001104659-19-051596

Insider Transaction Report

Form 4
Period: 2019-09-24
PRICE MICHAEL DENNIS
Chief Financial Officer
Transactions
  • Tax Payment

    Common Stock

    2019-09-24$0.76/sh3,926$2,98414,111 total
Footnotes (1)
  • [F1]The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. The vesting event occurred as the result of the acceleration of vesting on all outstanding equity awards under the Issuer's equity plans upon the closing of the previously announced transaction between, inter alia, the Issuer's operating subsidiary, Aegerion Pharmaceuticals, Inc. ("Aegerion") and Amryt Pharma plc on September 24, 2019. As a result of the transaction, the Issuer was divested of Aegerion, which constituted a change of control or sale event under the Issuer's equity plans.

Documents

1 file

Issuer

NOVELION THERAPEUTICS INC.

CIK 0000827809

Entity typeother

Related Parties

1
  • filerCIK 0001247313

Filing Metadata

Form type
4
Filed
Sep 25, 8:00 PM ET
Accepted
Sep 26, 6:30 PM ET
Size
5.5 KB